share_log

AbbVie | 8-K: Current report

AbbVie | 8-K: Current report

艾伯维公司 | 8-K:重大事件
美股SEC公告 ·  09/11 03:34

Moomoo AI 已提取核心信息

On September 6, 2024, AbbVie Inc. announced the approval of an amendment and restatement of the company's By-laws by its Board of Directors, effective immediately. The updated Third Amended and Restated By-laws include a change to the address of the company's registered agent and the removal of section 2.13(D)(iv), which had been challenged in a stockholder class action lawsuit. AbbVie stated that while they believe the provision to be lawful, it no longer holds practical value for the company and defending it is not considered the best use of resources. The full text of the amended By-laws is available as Exhibit 3.1 attached to the Current Report on Form 8-K.
On September 6, 2024, AbbVie Inc. announced the approval of an amendment and restatement of the company's By-laws by its Board of Directors, effective immediately. The updated Third Amended and Restated By-laws include a change to the address of the company's registered agent and the removal of section 2.13(D)(iv), which had been challenged in a stockholder class action lawsuit. AbbVie stated that while they believe the provision to be lawful, it no longer holds practical value for the company and defending it is not considered the best use of resources. The full text of the amended By-laws is available as Exhibit 3.1 attached to the Current Report on Form 8-K.
2024年9月6日,艾伯维公司董事会宣布批准修订公司章程,并立即生效。修订的第三版修订章程包括公司注册代理人地址的更改以及删除2.13(D)(iv)条款,该条款曾在股东集体诉讼中受到挑战。艾伯维表示,尽管他们认为这个条款是合法的,但它对公司已经没有实际价值,为其辩护也不被视为最佳资源利用。修订章程的完整文本作为附件3.1附在8-k表述的最新报告中。
2024年9月6日,艾伯维公司董事会宣布批准修订公司章程,并立即生效。修订的第三版修订章程包括公司注册代理人地址的更改以及删除2.13(D)(iv)条款,该条款曾在股东集体诉讼中受到挑战。艾伯维表示,尽管他们认为这个条款是合法的,但它对公司已经没有实际价值,为其辩护也不被视为最佳资源利用。修订章程的完整文本作为附件3.1附在8-k表述的最新报告中。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息